Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antitumor Immune Responses of Eribulin in Patients with Locally Advanced or Metastatic Breast Cancer

Trial Profile

Antitumor Immune Responses of Eribulin in Patients with Locally Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2018 New trial record
    • 01 May 2018 Results published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top